Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMT 95: Intensified vs Standard Chemotherapy in Childhood Rhabdomyosarcoma
NCT00162695Phase 3Terminated
- Sponsor
- Gustave Roussy
- Start
- Jul 1995
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, epirubicin and etoposide in rhabdomyosarcoma (RMS) and soft tissue sarcoma (STS) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Overall Survival at 3 years. Started Jul 1995; status: terminated.
02
Drugs
carboplatinepirubicinetoposide
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00162695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162695.